AI Article Synopsis
- Over a decade since the first biologic for psoriasis was approved, these medications have revolutionized treatment options.
- Traditional therapies like phototherapy still offer effective treatment, both alone and in combination with biologics, although their long-term effects on skin cancer are still unclear.
- Due to financial considerations, phototherapy remains an attractive option for treating psoriasis and other skin conditions, thanks to its proven efficacy, affordability, and compatibility with other treatments.
Article Abstract
Over 10 years have passed since the first approval of a biologic agent for the treatment of psoriasis. No one can argue that the arrival of this entirely new, highly effective class of medications has not forever changed the therapeutic landscape for psoriasis. Traditional treatments such as phototherapy, however, remain both viable and effective therapies, both as standalone treatments and in combination with biologics. In general, synergistic effects are noted for combinations utilizing phototherapy; however, the long-term impact of these combinations on skin cancer development has yet to be fully determined. Increasing financial pressures for cost-effective therapies augment the appeal of phototherapy and other traditional treatments as compared with the more costly biologics. Phototherapy also remains strong outside the realm of psoriasis, in the management of atopic dermatitis, vitiligo, and cutaneous T-cell lymphoma, among other conditions. Phototherapy will remain a cornerstone in the management of psoriasis as well as nonpsoriatic skin conditions, as its efficacy is well known, its financial cost is reasonable, it is readily compatible with other therapeutics, and its utility is historically proven.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/phpp.12088 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pathways to care for psychosis in rural Uganda: Mixed-methods study of individuals with psychosis, family members, and local leaders.
Glob Ment Health (Camb)
January 2025
Department of Psychiatry Mbarara University of Science and Technology, Mbarara, Uganda.
Background: Low- and middle-income countries (LMICs) bear a disproportionate burden of mental illness, with limited access to biomedical care. This study examined pathways to care for psychosis in rural Uganda, exploring factors influencing treatment choices.
Methods: We conducted a mixed-methods study in Buyende District, Uganda, involving 67 in-depth interviews and 4 focus group discussions (data collection continued until thematic saturation was reached) with individuals with psychotic disorders, family members, and local leaders.
Assessment of human emotional reactions to visual stimuli "deep-dreamed" by artificial neural networks.
Front Psychol
December 2024
Department of Computer Science and Engineering, University of Notre Dame, Notre Dame, IN, United States.
Introduction: While the fact that visual stimuli synthesized by Artificial Neural Networks (ANN) may evoke emotional reactions is documented, the precise mechanisms that connect the strength and type of such reactions with the ways of how ANNs are used to synthesize visual stimuli are yet to be discovered. Understanding these mechanisms allows for designing methods that synthesize images attenuating or enhancing selected emotional states, which may provide unobtrusive and widely-applicable treatment of mental dysfunctions and disorders.
Methods: The Convolutional Neural Network (CNN), a type of ANN used in computer vision tasks which models the ways humans solve visual tasks, was applied to synthesize ("dream" or "hallucinate") images with no semantic content to maximize activations of neurons in precisely-selected layers in the CNN.
The systemic inflammation response index (SIRI) predicts survival in advanced non-small cell lung cancer patients undergoing immunotherapy and the construction of a nomogram model.
Front Immunol
December 2024
Department of Radiation Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Afliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China.
Background: Inflammation and immune evasion are associated with tumorigenesis and progression. The Systemic Inflammation Response Index (SIRI) has been proposed as a pre-treatment peripheral blood biomarker. This study aims to compare the relationship between SIRI, various serum biomarkers, and the prognosis of NSCLC patients before and after treatment.
View Article and Find Full Text PDFPrecision medicine using molecular-target drugs in psoriatic arthritis.
Ther Adv Musculoskelet Dis
January 2025
The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, 1-1 Iseigaoka, Yahata-nishi, Kitakyushu 807-8555, Japan.
Psoriatic arthritis (PsA) presents various clinical manifestations, including skin lesions, peripheral arthritis, axial involvement, enthesitis, nail involvement, dactylitis, and uveitis. In addition, it causes a high incidence of lifestyle-related diseases and an increase in cerebrovascular and cardiovascular events. As the pathology of PsA has been clarified, molecular-targeted drugs targeting tumor necrosis factor-α, interleukin (IL)-17A, IL-17A/F, IL-17 receptor, IL-12/23(p40), IL-23p19, Cytotoxic T-lymphocyte Antigen-4 (CTLA-4), Janus kinase, and phosphodiesterase-4 have been developed and are widely used in clinical practice.
View Article and Find Full Text PDFRNA nanotherapeutics for hepatocellular carcinoma treatment.
Theranostics
January 2025
Center for Nanomedicine and Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide, particularly due to the limited effectiveness of current therapeutic options for advanced-stage disease. The efficacy of traditional treatments is often compromised by the intricate liver microenvironment and the inherent heterogeneity. RNA-based therapeutics offer a promising alternative, utilizing the innovative approach of targeting aberrant molecular pathways and modulating the tumor microenvironment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!